Dacarbazine | List of Frontiers open access articles

Original Research

Published on 03 Dec 2021

Transcriptomic Profiling Revealed Plexin A2 Downregulation With Migration and Invasion Alteration in Dacarbazine-Treated Primary Melanoma Cells

in Molecular and Cellular Oncology

Anna Tyumentseva
Anton Averchuk
Nadezhda Palkina
Ivan Zinchenko
Anton Moshev
Andrey Savchenko
Tatiana Ruksha

Frontiers in Oncology

doi 10.3389/fonc.2021.732501

3,001 views
5 citations

Case Report

Published on 19 Apr 2018

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors

in Cancer Immunity and Immunotherapy

Marjorie Faure
Philippe Rochigneux
Daniel Olive
Sébastien Taix
Isabelle Brenot-Rossi
Marine Gilabert

Frontiers in Immunology

doi 10.3389/fimmu.2018.00797

10,472 views
39 citations

Original Research

Published on 26 Jun 2020

Pre-treatment With PLGA/Silibinin Nanoparticles Mitigates Dacarbazine-Induced Hepatotoxicity

in Nanobiotechnology

Mikhail Durymanov
Anastasia Permyakova
Joshua Reineke

Frontiers in Bioengineering and Biotechnology

doi 10.3389/fbioe.2020.00495

5,818 views
17 citations

Case Report

Published on 05 Dec 2024

Clonally unrelated HL-type RS manifested as hemophagocytic syndrome: a case report and literature review

in Hematologic Malignancies

Xiaoman Zheng
Wenshuang Ding
Zhigang Zhu
Junping Li
Weijie Zhong

Frontiers in Oncology

doi 10.3389/fonc.2024.1472560

1,786 views

Original Research

Published on 21 Apr 2023

Dacarbazine-encapsulated solid lipid nanoparticles for skin cancer: physical characterization, stability, in-vivo activity, histopathology, and immunohistochemistry

in Skin Cancer

Sankha Bhattacharya
Satyam Sharma

Frontiers in Oncology

doi 10.3389/fonc.2023.1102269

5,944 views
16 citations

Original Research

Published on 17 Mar 2021

LncRNA POU3F3 Contributes to Dacarbazine Resistance of Human Melanoma Through the MiR-650/MGMT Axis

in Skin Cancer

Kai Wu
Qiang Wang
Yu-Lin Liu
Zhuo Xiang
Qing-Qing Wang
Li Yin
Shun-Li Liu

Frontiers in Oncology

doi 10.3389/fonc.2021.643613

4,287 views
18 citations

Original Research

Published on 23 Aug 2024

Acetylcytidine modification of DDX41 and ZNF746 by N-acetyltransferase 10 contributes to chemoresistance of melanoma

in Cancer Molecular Targets and Therapeutics

Li Wang
Yuefen Zeng
Ying Zhang
Yun Zhu
Shuangyan Xu
Zuohui Liang

Frontiers in Oncology

doi 10.3389/fonc.2024.1448890

3,441 views
3 citations

Original Research

Published on 17 Feb 2022

Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy

in Biomaterials

Wei Xiong
Zhengdong Guo
Baoyan Zeng
Teng Wang
Xiaowei Zeng
Wei Cao
Daizheng Lian

Frontiers in Bioengineering and Biotechnology

doi 10.3389/fbioe.2022.847901

7,619 views
34 citations

Case Report

Published on 20 Mar 2024

Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report

in Cancer Immunity and Immunotherapy

Tanja Fetter
Simon Fietz
Maya Bertlich
Christine Braegelmann
Luka de Vos-Hillebrand
Joerg Wenzel
Annkristin Heine
Jennifer Landsberg
Philipp Jansen

Frontiers in Immunology

doi 10.3389/fimmu.2024.1342845

6,810 views
3 citations

Case Report

Published on 29 Jan 2024

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study

in Skin Cancer

Jacek Calik
Piotr Dzięgiel
Natalia Sauer

Frontiers in Oncology

doi 10.3389/fonc.2024.1332362

4,723 views
1 citation

Clinical Trial

Published on 06 Mar 2020

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study

in Pharmacology of Anti-Cancer Drugs

Francesca Urbani
Virginia Ferraresi
Imerio Capone
Iole Macchia
Belinda Palermo
Carmen Nuzzo
Angela Torsello
Patrizio Pezzotti
Diana Giannarelli
Anna Fausta Pozzi

Frontiers in Oncology

doi 10.3389/fonc.2020.00202

6,083 views
7 citations

Original Research

Published on 22 Jan 2026

Treatment of metastatic bladder paraganglioma with cadonilimab plus radiotherapy: a case report and literature review

in Precision Medicine

RiHan Wu
ZiRui Wang
YuanRui Bai
Yihui Liu
Chunhui Dong
Ling Chen

Frontiers in Medicine

doi 10.3389/fmed.2025.1718146

530 views

Original Research

Published on 22 Dec 2016

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

in Cancer Immunity and Immunotherapy

Anja Derer
Martina Spiljar
Monika Bäumler
Markus Hecht
Rainer Fietkau
Benjamin Frey
Udo S. Gaipl

Frontiers in Immunology

doi 10.3389/fimmu.2016.00610

15,440 views
131 citations

Original Research

Published on 25 Oct 2024

Exploring the complexity, treatment challenges, and outcomes in pediatric nodular lymphocyte predominant Hodgkin lymphoma: a perspective from a low–middle-income country

in Pediatric Oncology

Youssef Madney
Amr Abdalla
Soha Ahmed
Marwa Romeih
Sally Fikry
Engy Mohammed
Hala Taha
Mohamed Zaghloul
Eman Attia

Frontiers in Oncology

doi 10.3389/fonc.2024.1432650

2,760 views
3 citations

Original Research

Published on 18 May 2023

Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha

in Cancer Immunity and Immunotherapy

Federica Moschella
Carla Buccione
Irene Ruspantini
Luciano Castiello
Andrea Rozo Gonzalez
Floriana Iacobone
Virginia Ferraresi
Belinda Palermo
Paola Nisticò
Filippo Belardelli

Frontiers in Oncology

doi 10.3389/fonc.2023.1145667

2,880 views
4 citations

Original Research

Published on 07 Oct 2024

Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition

in Skin Cancer

Georgios Lyrarakis
Michael Liontos
Amalia Anastasopoulou
Spyridon Bouros
Aikaterini Gkoufa
Panagiotis Diamantopoulos
Helen Gogas
Dimitrios C. Ziogas

Frontiers in Oncology

doi 10.3389/fonc.2024.1420879

3,691 views
3 citations

Articles

Transcriptomic Profiling Revealed Plexin A2 Downregulation With Migration and Invasion Alteration in Dacarbazine-Treated Primary Melanoma Cells

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors

Pre-treatment With PLGA/Silibinin Nanoparticles Mitigates Dacarbazine-Induced Hepatotoxicity

Clonally unrelated HL-type RS manifested as hemophagocytic syndrome: a case report and literature review

Dacarbazine-encapsulated solid lipid nanoparticles for skin cancer: physical characterization, stability, in-vivo activity, histopathology, and immunohistochemistry

LncRNA POU3F3 Contributes to Dacarbazine Resistance of Human Melanoma Through the MiR-650/MGMT Axis

Acetylcytidine modification of DDX41 and ZNF746 by N-acetyltransferase 10 contributes to chemoresistance of melanoma

Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy

Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study

Treatment of metastatic bladder paraganglioma with cadonilimab plus radiotherapy: a case report and literature review

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

Exploring the complexity, treatment challenges, and outcomes in pediatric nodular lymphocyte predominant Hodgkin lymphoma: a perspective from a low–middle-income country

Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha

Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition